Jardiance is first diabetes drug to improve CV outcomes - PMLiVE
Torrent Pharma, Boehringer Ingelheim India ink pact to co-market anti-diabetic drug - The Hindu BusinessLine
Boehringer Ingelheim announce the launch of the first anti-diabetic medication to reduce CV risk by one third | mea.boehringer-ingelheim.com
The Arab Drug Store - Boehringer Ingelheim | Jardiance
Crunch time for diabetes pills hoping to keep up with Jardiance | Evaluate
Jardiance Tablet – Know Its Uses, Benefits, Interaction, Precautions, and Side Effects - Breathe Well-Being
Boehringer Ingelheim Human Pharma & Animal Health Products | Boehringer Ingelheim
The Arab Drug Store - Boehringer Ingelheim | Trajenta®
Boehringer Ingelheim, Lupin tie up to co-market anti-diabetes drug - Times of India
Weber Shandwick wins Boehringer Ingelheim diabetes drug brief
Boehringer Ingelheim taps Insilico Medicine for AI drug target collaboration | Fierce Biotech
Boehringer Ingelheim type 2 diabetes drug misses endpoint
FDA Approves Type 2 Diabetes Drug from Boehringer Ingelheim and Lilly
Torrent Pharma inks pact with Boehringer Ingelheim to co-market anti-diabetic drug in India - BusinessToday
jardiance: Boehringer Ingelheim's diabetes pill Jardiance gets CDSCO nod for use against heart failure - The Economic Times
HC restrains pharma companies from infringing Boehringer Ingelheim diabetes drug Linagliptin
Torrent Pharma, Boehringer Ingelheim India to co-market diabetes drug | Business Standard News
indian pharma: Boehringer Ingelheim obtains interim injunction against four Indian drug cos from selling its diabetes drug - The Economic Times
Torrent Pharma collaborates with Boehringer Ingelheim India to co-market its anti-diabetic drug, its fixed
Cipla and Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs | Cipla
Dr Reddys Labs: Boehringer Ingelheim gets interim injunction against Dr. Reddy's Labs, MSN Labs against copies of anti-diabetes drug - The Economic Times
Torrent Pharma, Boehringer Ingelheim India To Co-Market Diabetes Drug
Boehringer sees turbocharged diabetes unit driving future growth | Fierce Pharma
Boehringer Ingelheim 2021: Keeping its focus on steady innovation – PharmaLive
FDA reviews Jardiance as cardiovascular diabetes treatment | Pharmafile
Boehringer-Lilly win expanded European licence for Trajenta - PMLiVE
